Bridgewater, NJ (USA), June 15, 2017 – Amneal Pharmaceuticals LLC is pleased to announce the launch of ezetimibe tablets in 10 mg strength.
Amneal’s generic, an AB-rated therapeutic equivalent to Zetia®, is available in 30-, 90- and 500-count sizes.
The product began shipping June 13th from the Amneal Kentucky distribution center and is available for purchase through major wholesalers and distributors.
Annual U.S. sales of Zetia® were nearly $2.7 billion according to April 2017 IMS market data.
Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 4,500 employees in its operations in North America, Asia, Australia and Europe, working together to bring high-quality, affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit www.amneal.com.
All trademarks listed in this release are property of their respective owners.
Jim Luce (sales)
Executive Vice President, Sales & Marketing
Cheryl Lechok (media)
President, Cheryl Lechok Communications